(IN BRIEF) Roche and Nurix Therapeutics have entered into an exclusive global licensing and collaboration agreement to co-develop and co-commercialise bexobrutideg, also known as NX-5948, an investigational oral BTK degrader with potential applications across malignant haematology, immunology and neurology. The … Read the full press release
Posted in Business, European Union, Financial, Government, Healthcare, Industrial, Investment, Law, Management, Marketing, Pharma & Biotech, Science, Switzerland, Technology
Tagged Arthur T Sands, B-cell malignancies, bexobrutideg, brain-penetrant therapy, Bruton’s tyrosine kinase, BTK, BTK degrader, BTK inhibitors, chronic lymphocytic leukaemia, chronic spontaneous urticaria, CLL, co-commercialisation, co-development, CSU, Hart-Scott-Rodino Antitrust Improvements Act, immunology, Immunology and Neurology Pipeline with Global Bexobrutideg Collaboration, kinase activity, Levi Garraway, licensing agreement, malignant haematology, MS, multiple sclerosis, Neurology, NHL, Non-Hodgkin lymphoma, Nurix Therapeutics, NX-5948, oncology pipeline, oral therapy, Phase 3 clinical trial, relapsed or refractory B-cell malignancies, Roche, Roche and Nurix Announce Up to USD 2.3 Billion Collaboration to Develop and Commercialise Bexobrutideg, Roche and Nurix Therapeutics Partner on Potential Best-in-Class Targeted Protein Degrader for B-Cell Malignancies, Roche oncology, Roche Strengthens Oncology, scaffolding function, Switzerland, targeted protein degradation, targeted protein degrader, treatment resistance, United States, USD 2.3 billion deal value, USD 700 million upfront payment
(IN BRIEF) Sanofi and Regeneron have received European Commission approval for Dupixent to treat children aged two to 11 with chronic spontaneous urticaria, marking the first targeted therapy available for this condition in young patients. Supported by data from the … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Alyssa Johnsen, biologics, chronic spontaneous urticaria, clinical trials, CSU, CUPIDKids, dupilumab, Dupixent, EU approval, European Commission, George D. Yancopoulos, immunology, LIBERTY CUPID, pediatric dermatology, pediatric treatment, Regeneron Pharmaceuticals, Sanofi, Sanofi and Regeneron Advance Pediatric Care with EU Approval of Dupixent for Chronic Spontaneous Urticaria, type 2 inflammation
(IN BRIEF) Novartis has presented new data at the 2024 European Academy of Allergy and Clinical Immunology (EAACI) Congress, showcasing the sustained efficacy and safety of remibrutinib, a selective Bruton’s tyrosine kinase (BTK) inhibitor, in chronic spontaneous urticaria (CSU). Results … Read the full press release
TOP-LINE DATA FROM REMIX-1 AND REMIX-2 STUDIES DEMONSTRATE SIGNIFICANT SYMPTOM IMPROVEMENT (IN BRIEF) Novartis has unveiled promising results from Phase III trials for remibrutinib, a potent Bruton’s tyrosine kinase (BTK) inhibitor, targeting chronic spontaneous urticaria (CSU). The REMIX-1 and REMIX-2 … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?